Here are three points:
1. The groups will develop a pair of antibodies to prevent and treat MERS.
2. HHS will allot $8.9 million to Regeneron for manufacturing, the investigational new drug application and an National Institutes of Health clinical trial.
3. Currently, no drugs exist to treat or prevent MERS.
More articles on quality & infection control:
The benefits of a team-based approach to ASC infection control compliance
5 things to know about the global over-the-counter drug market
How to effectively communicate adverse events to family members — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.